Fri.Apr 26, 2024

article thumbnail

Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose

Fierce Pharma

Ten years after dipping its toes into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained FDA approval for the acquired treatment. | Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. The U.S. regulator has endorsed Beqvez for adults with the bleeding disorder hemophilia B.

FDA 322
article thumbnail

Johns Hopkins Is Teaming Up With Healthy.io to Improve Diabetic Patients’ Wound Care

MedCity News

Johns Hopkins Hospital teamed up with Healthy.io, a company that offers smartphone-based technology to improve wound care management for diabetic patients. The partners are conducting a 120-person study to measure the impact of the startup’s technology. The post Johns Hopkins Is Teaming Up With Healthy.io to Improve Diabetic Patients’ Wound Care appeared first on MedCity News.

Patients 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gilead writes $2.4B off Trodelvy as CEO underscores ‘time of focused execution’

Fierce Pharma

After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition. | After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. With a busy year ahead across therapeutic areas, CEO Dan O'Day emphasized a "time of focused execution.

306
306
article thumbnail

Owlstone secures $6.5M for breath-based diagnostics for infectious disease

pharmaphorum

Owlstone Medical has secured a $5 million equity investment and initial $1.5 million grant funding, committed by the Bill and Melinda Gates Foundation, for development of breath-based diagnostic solutions to improve outcomes in the developing world.

Medical 114
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod

Fierce Pharma

AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. | As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis.

Sales 279
article thumbnail

Benefits of 3D printing for personalised medicine formulation

European Pharmaceutical Review

A paper has reported the first time that 3D printing has facilitated two active pharmaceutical ingredients (APIs) to be combined in the same formulation. This method enables the number of administrations of the drug evaluated to be minimised, the researchers found. The authors aimed to evaluate and compare the efficacy and acceptability of chewable 3D printed medicines containing citrulline, isoleucine, and valine alone or in combination.

Medicine 110

More Trending

article thumbnail

BMI: A Flawed Measure of Health

MedCity News

It’s time we move beyond BMI and adopt a holistic approach to truly gauge health. The post BMI: A Flawed Measure of Health appeared first on MedCity News.

Biopharma 116
article thumbnail

AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again

Fierce Pharma

For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atop | For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown better skin clearance than Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD).

Patients 130
article thumbnail

Driving Safer Care for All with Connected Healthcare Operations

MedCity News

Addressing preventable harm starts with breaking down the data silos that exist within the healthcare landscape and pulling disparate systems together through connected healthcare operations. The post Driving Safer Care for All with Connected Healthcare Operations appeared first on MedCity News.

article thumbnail

AbbVie JAK inhibitor shows potential in novel atopic dermatitis head-to-head trial

European Pharmaceutical Review

AbbVie has revealed positive topline results from the first head-to-head trial in atopic dermatitis assessing RINVOQ ® (upadacitinib) at a starting dose of 15mg daily versus DUPIXENT ® ( dupilumab ) at its labelled dose. The Phase IIIb/IV LEVEL UP study evaluated the efficacy and safety of these drugs in individuals 12 years old and older with moderate-to-severe atopic dermatitis.

Safety 98
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Moderna banks on OpenAI to accelerate mRNA research 

pharmaphorum

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and manufacturing operations.

article thumbnail

Pfizer’s First Gene Therapy Approval Sets Up a Showdown With CSL in Hemophilia B

MedCity News

The FDA has approved Beqvez, a Pfizer gene therapy developed for moderate-to-severe hemophilia B. The one-time treatment carries a $3.5 million price tag, the same as a CSL Behring gene therapy already available for treating the inherited bleeding disorder. The post Pfizer’s First Gene Therapy Approval Sets Up a Showdown With CSL in Hemophilia B appeared first on MedCity News.

FDA 97
article thumbnail

ETH develops AI algorithm for drug discovery based on 3D protein surface

pharmaphorum

Chemists at ETH Zurich have developed a new computer process that enables the generation of active pharmaceutical ingredients at speed, based on a protein’s three-dimensional surface.

article thumbnail

Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine

MedCity News

This rapidly growing field marries bioinformatics and pharmacology and represents a transformative new era of precision medicine and highly personalized treatments. The post Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine appeared first on MedCity News.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.

PharmaVoice

Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.

80
article thumbnail

Facilities of the Future: Meeting the Demands of Breakthrough Therapeutics

PharmaTech

As breakthrough therapeutics in the pharma pipeline approach commercialization, pharmaceutical manufacturing facilities must evolve to meet demand.

article thumbnail

Two RNA-binding proteins could contribute to cancer therapy development

PharmaTimes

The paper identifies the roles of LARP4A and LARP4B in sarcoma and carcinoma cancers

94
article thumbnail

StartUPDATES: New Developments from Healthcare Startups

MedCity News

Check out news from Alpha Sophia, Handl Health, Alaffia Health, and Summer Health The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma Pulse 4/26/24: Amazon Introduces Custom AI Capabilities, Crafting Culturally Sensitive Messages to Reach Diverse Audience & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 102
article thumbnail

Scientists reveal new method that could reduce waste from drug manufacturing

PharmaTimes

The new method could help to prevent severe side effects caused by enantiomer drugs

article thumbnail

FDA Approves Pfizer’s Beqvez for the Treatment of Adults with Moderate to Severe Hemophilia B

PharmExec

Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.

FDA 52
article thumbnail

How AI can improve the virtual experience for healthcare providers and patients

Impetus Digital

This is a guest article and does not necessarily reflect the views and values of Impetus Digital. As we continue to transition towards and rely more heavily on artificial intelligence (AI) as a practical, day-to-day tool, an increasing number of sectors are choosing to implement this futuristic technology. This is no truer than in the healthcare sector.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA Approves Label Update for Gilead’s Biktarvy to Include Pregnant Adults With HIV

PharmExec

Approval update comes as a result of findings from Study 5310, which addressed Biktarvy’s pharmacokinetics, safety, and efficacy during pregnancy and postpartum periods in patients with HIV.

Safety 52
article thumbnail

No One Likes Healthcare Adversting, But They Could.

PM360

Healthcare advertising rarely demonstrates that it knows how to reward customers for their time, or shows what a smart creative idea can do. We need a better approach. Making memorable creative isn’t easy but it is possible in healthcare. There are just certain must haves. The first must have is obviously a talent for creative. Creative talent is the love child of imagination and a sense of humor.

article thumbnail

Going Beyond Visuals to Connect with Diverse Audiences

PharmExec

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers can utilize to connect with diverse audiences on a deeper level

article thumbnail

Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

Pharmaceutical Technology

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) this year amid ongoing macroeconomic uncertainties, fluctuating interest rates, and evolving Medicare drug price negotiations.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Coya Therapeutics CEO Discusses Company's Treatment Pipeline

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at the organization's pipeline.

52
article thumbnail

Regeneron and Mammoth team up to develop gene editing therapies

Pharmaceutical Technology

Regeneron Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapies.

article thumbnail

CVS Health Announces New Work Force Development and Community Center in Louisiana

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Multiply Labs and GenScript partner on cell isolation automation

Pharmaceutical Technology

Robotics company Multiply Labs has partnered with global life-sciences service provider GenScript Biotech to automate the cell isolation phase in cell therapy manufacturing.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A